Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
| 9.51 | |
| 9.51 | |
| - | |
| 9.51 | |
| 9.51 | |
| 9-10.18 | |
| 2 028 M | |
| 213 M | |
| 932 M | |
| 0.373 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Amidst a complex landscape where global markets display mixed signals, investors are increasingly turning their attention to value and small-cap stocks. This shift comes as major indices like the Dow ...
Strong growth trajectory maintained with Net Sales increase of 6.7% to a total of €497.2 MM, EBITDA of €104.5 MM (+3.2% YoY) driven by increased overall sales and strong performance of biologics p...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
